CGI1746

Target: CGI1746 targets BTK as a potent, highly selective allosteric small-molecule inhibitor.

Mechanism of Action: CGI1746 can be used as a BTK-binding ligand for degrader design based on allosteric kinase recognition. In a PROTAC, a CGI1746-derived warhead binds BTK, and a linker connects it to an E3 ligase ligand. The bifunctional molecule must recruit BTK and the E3 ligase concurrently, generating a ternary complex with geometry suitable for ubiquitin transfer. If BTK lysines are productively exposed to the ligase, BTK is polyubiquitinated and directed to proteasomal degradation, enabling target depletion rather than inhibition alone. This establishes a testable protein-depletion mechanism for research assays.

• PROTAC E3 Ligase Recruitment: CGI1746 can be used as a ligand module to assemble PROTACs that recruit an E3 ubiquitin ligase to the target protein. This enables ubiquitination and proteasome-dependent degradation, allowing researchers to probe loss-of-function phenotypes and define degradation potency versus occupancy-driven effects in cellular models.

• Targeted Protein Degradation Studies: CGI1746-based PROTAC constructs support systematic evaluation of targeted degradation across experimental conditions. By varying linker length and PROTAC stoichiometry, investigators can map degradation kinetics, determine effective concentration ranges, and compare degradation outcomes with corresponding target inhibition to clarify when degradation provides superior biological impact.

• Mechanism and Pathway Dissection: CGI1746-enabled PROTACs are suitable for mechanistic studies of ubiquitin-proteasome processing. Researchers can use proteasome inhibition or ubiquitination pathway perturbation to confirm degradation dependence, quantify ubiquitinated intermediates, and distinguish direct degradation from indirect pathway effects in target-expressing systems.

• Cellular Phenotype Optimization: CGI1746 can be incorporated into PROTAC designs to optimize cellular phenotypes driven by selective protein removal. Researchers can screen PROTAC variants for improved degradation selectivity, evaluate downstream signaling rewiring, and assess whether degradation correlates with functional readouts such as proliferation, apoptosis, or transcriptional changes.

CGI1746 is a selective BTK inhibitor reported to stabilize an inactive BTK conformation, making it a useful reversible BTK ligand for degrader exploration. Its benzamide-pyrazinone scaffold lacks a covalent acrylamide, which may aid comparison with covalent BTK warheads. This molecule is described in detail below.

Structure: The structure contains a tert-butyl benzamide linked to a substituted anilino pyrazinone bearing a morpholine-4-carbonyl phenyl group. The aromatic amide, pyrazinone, and morpholine amide create a polar but highly aromatic BTK-binding framework.

Reactivity: For reversible BTK degrader design, the morpholine-carbonyl phenyl or tert-butyl benzamide periphery may be evaluated as a linker exit vector, while the pyrazinone core should generally be preserved until binding data demonstrate tolerance. PEG, alkyl, or amide-linked linkers can be paired with CRBN or VHL ligands, and CGI1746-derived degraders may be especially useful for comparing reversible BTK recruitment with covalent BTK PROTAC analogues.